Abstract
FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have